Home › Pulmonary Arterial Hypertension › Washington
Pulmonary Arterial Hypertension clinical trials in Washington, DC
4 studies for Pulmonary Arterial Hypertension are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Spironolactone for Pulmonary Arterial Hypertension
RecruitingPhase 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
RecruitingPhase 3
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
RecruitingPhase 2
- George Washington University Medical, Washington D.C.
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
RecruitingPhase 2
- Children's National Medical Center ( Site 1600), Washington D.C.
Pulmonary Arterial Hypertension trials in other cities
- Durham, NC7 studies
- Cincinnati, OH7 studies
- Mountain View, CA7 studies
- Kansas City, KS7 studies
- Boston, MA7 studies
- Aurora, CO7 studies
- Nashville, TN7 studies
- Philadelphia, PA6 studies
- New York City, NY5 studies
- Seattle, WA5 studies
- Houston, TX4 studies
- Louisville, KY4 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.